Benno Therapeutics SRL
Benno Therapeutics reported total assets of 56,724 € at the end of the 2025 financial year (annual accounts filed with the NBB on 15 Jun 2026).
The score of Benno Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Benno Therapeutics's annual accounts
| 2025 | |
|---|---|
| Net result | −790,201 € |
| Equity | −506,759 € |
| Cash | 35,366 € |
| EBITDA | −194,008 € |
| Total assets | 56,724 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 15 Jun 2026
Benno Therapeutics's financial analysis
- Solvency-893.4%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Benno Therapeutics
Benno Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1006.661.347
- VAT number
- BE1006661347
- Peppol
- Registered · 0208:1006661347 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 01 Mar 2024
- Registered office
- 3001 Leuven
- Latest accounts
- 2025 · filed on 15 Jun 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Benno Therapeutics (SRL) has been based in Leuven since 2024, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 790,201 € and equity of −506,759 €; its revenue is not published. Its solvency stands at -893.4%, below the median of its sector (60.4%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Benno Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- CTTec Research and experimental development on natural sciences and engineering Menen · balance sheet 259,750 €
- JN-RD Research and experimental development on natural sciences and engineering Oreye · balance sheet 67,834 €
- Biograbbit Research and experimental development on natural sciences and engineering Dendermonde · balance sheet 61,503 €
- Yagh Penn Consulting Research and experimental development on natural sciences and engineering Bertem · balance sheet 34,428 €
- Aquature Technologies Research and experimental development on natural sciences and engineering Antwerp · balance sheet 122,734 €
- Shift Happens Research and experimental development on natural sciences and engineering Ghent · balance sheet 62,809 €
- FoxBioPath Research and experimental development on natural sciences and engineering Duffel · balance sheet 103,842 €
- D.C.V.E. Solutions All other professional, scientific and technical activities n.e.c. Kortenaken · balance sheet 97,996 €
Frequently asked questions about Benno Therapeutics
What is the revenue of Benno Therapeutics?
Benno Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Benno Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE1006661347 for Benno Therapeutics, if the company is VAT-registered. Its company number (CBE) is 1006.661.347.
Where is the registered office of Benno Therapeutics?
According to the CBE register, the registered office of Benno Therapeutics is in 3001 Leuven.
What is the equity of Benno Therapeutics?
At the close of the 2025 financial year, the equity of Benno Therapeutics amounts to -506,759 €, a solvency of -893.4% of total assets.
Who manages Benno Therapeutics?
The register lists 2 active mandates at Benno Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Benno Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →